Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
Status:
Completed
Trial end date:
2018-11-28
Target enrollment:
Participant gender:
Summary
Phase III trial evaluating raltegravir as an alternative to efavirenz for antiretroviral
treatment of HIV-infected patients with tuberculosis.
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Collaborators:
Merck Sharp & Dohme Corp. Ministry of Health, Brazil